Any feedback?
Literature summary for 3.4.23.38 extracted from
- Plasmepsins as antimalarial targets (2000), Curr. Opin. Drug Discov. Devel., 3, 624-629.
Inhibitors
| Inhibitors | Comment | Organism | Structure |
|---|---|---|---|
| 17-benzyl-14-[2-(3,3-dimethyl-butyrylamino)-3-methyl-butyrylamino]-18-hydroxy-2-isopropyl-3,8,15,20-tetraoxo-1,4,9,16-tetraaza-cycloicosane-5-carboxylic acid carbamoylmethyl-amide | - |
Plasmodium falciparum |  |
| additional information | none of the inhibitors analyzed to date have sufficient selectivity for plasmepsin I and II, compared to their human counterparts | Plasmodium falciparum | |
| piperidine-4-carboxylic acid [3-[2-(3-chloro-phenoxy)-acetylamino]-2-hydroxy-4-phenyl-butyl]-[2-(4-methoxy-phenyl)-ethyl]-amide | - |
Plasmodium falciparum | |
Organism
| Organism | UniProt | Comment | Textmining |
|---|---|---|---|
| Plasmodium falciparum | - |
- |
- |
Posttranslational Modification
| Posttranslational Modification | Comment | Organism |
|---|---|---|
| proteolytic modification | the proenzyme has an unusually long propart of 125 amino acid residues that mediates type II membrane anchoring of the proenzyme, activation occurs by removal of the propart | Plasmodium falciparum |
Ki Value [mM]
| Ki Value [mM] | Ki Value maximum [mM] | Inhibitor | Comment | Organism | Structure |
|---|---|---|---|---|---|
| 0.00000001 | - |
17-Benzyl-14-[2-(3,3-dimethyl-butyrylamino)-3-methyl-butyrylamino]-18-hydroxy-2-isopropyl-3,8,15,20-tetraoxo-1,4,9,16tetraaza-cycloicosane-5-carboxylic acid carbamoylmethyl-amide | - |
Plasmodium falciparum | |
| 0.000006 | - |
Ro40-5576 | - |
Plasmodium falciparum | |
Use of this online version of BRENDA is free under the CC BY 4.0 license. See terms of use for full details.
Release 2023.1 (January 2023)
Legal
Curated at
Member of
